These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2930 related articles for article (PubMed ID: 7729952)

  • 1. Induction and characterization of cytotoxic T-lymphocytes recognizing a mutated p21ras peptide presented by HLA-A*0201.
    Van Elsas A; Nijman HW; Van der Minne CE; Mourer JS; Kast WM; Melief CJ; Schrier PI
    Int J Cancer; 1995 May; 61(3):389-96. PubMed ID: 7729952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction in transgenic mice of HLA-A2.1-restricted cytotoxic T cells specific for a peptide sequence from a mutated p21ras protein.
    Escobar P; Yu Z; Terskikh A; Holmes N; Corradin G; Mach JP; Healy F
    Clin Exp Immunol; 1999 May; 116(2):214-9. PubMed ID: 10337009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T-cell immunity to oncogenic proteins including mutated ras and chimeric bcr-abl.
    Cheever MA; Chen W; Disis ML; Takahashi M; Peace DJ
    Ann N Y Acad Sci; 1993 Aug; 690():101-12. PubMed ID: 8103658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a human CD8+ T lymphocyte neo-epitope created by a ras codon 12 mutation which is restricted by the HLA-A2 allele.
    Bergmann-Leitner ES; Kantor JA; Shupert WL; Schlom J; Abrams SI
    Cell Immunol; 1998 Aug; 187(2):103-16. PubMed ID: 9732698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Memory T cells of a patient with follicular thyroid carcinoma recognize peptides derived from mutated p21 ras (Gln-->Leu61).
    Gedde-Dahl T; Spurkland A; Eriksen JA; Thorsby E; Gaudernack G
    Int Immunol; 1992 Nov; 4(11):1331-7. PubMed ID: 1282032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A wild-type sequence p53 peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize squamous cell carcinomas of the head and neck.
    Eura M; Chikamatsu K; Katsura F; Obata A; Sobao Y; Takiguchi M; Song Y; Appella E; Whiteside TL; DeLeo AB
    Clin Cancer Res; 2000 Mar; 6(3):979-86. PubMed ID: 10741724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide.
    Ohminami H; Yasukawa M; Fujita S
    Blood; 2000 Jan; 95(1):286-93. PubMed ID: 10607714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unconventional cytotoxic T lymphocyte recognition of synthetic peptides corresponding to residues 1-23 of Ras protein.
    Yin L; Thomas C; Hsuan JJ; Stauss HJ
    Eur J Immunol; 1994 Sep; 24(9):1988-92. PubMed ID: 8088318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations.
    Abrams SI; Khleif SN; Bergmann-Leitner ES; Kantor JA; Chung Y; Hamilton JM; Schlom J
    Cell Immunol; 1997 Dec; 182(2):137-51. PubMed ID: 9514698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues.
    Valmori D; Fonteneau JF; Lizana CM; Gervois N; Liénard D; Rimoldi D; Jongeneel V; Jotereau F; Cerottini JC; Romero P
    J Immunol; 1998 Feb; 160(4):1750-8. PubMed ID: 9469433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of overlapping epitopes in mutant ras oncogene peptides that activate CD4+ and CD8+ T cell responses.
    Abrams SI; Stanziale SF; Lunin SD; Zaremba S; Schlom J
    Eur J Immunol; 1996 Feb; 26(2):435-43. PubMed ID: 8617315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytotoxic T-lymphocyte responses against mutated p21 ras peptides: an analysis of specific T-cell-receptor gene usage.
    Juretic A; Jürgens-Göbel J; Schaefer C; Noppen C; Willimann TE; Kocher T; Zuber M; Harder F; Heberer M; Spagnoli GC
    Int J Cancer; 1996 Nov; 68(4):471-8. PubMed ID: 8945618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of human cytotoxic T lymphocytes that preferentially recognise tumour cells bearing a conformational p53 mutant.
    McArdle SE; Rees RC; Mulcahy KA; Saba J; McIntyre CA; Murray AK
    Cancer Immunol Immunother; 2000 Oct; 49(8):417-25. PubMed ID: 11043848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BCR-ABL fusion regions as a source of multiple leukemia-specific CD8+ T-cell epitopes.
    Kessler JH; Bres-Vloemans SA; van Veelen PA; de Ru A; Huijbers IJ; Camps M; Mulder A; Offringa R; Drijfhout JW; Leeksma OC; Ossendorp F; Melief CJ
    Leukemia; 2006 Oct; 20(10):1738-50. PubMed ID: 16932347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HLA-A3 restricted mutant ras specific cytotoxic T-lymphocytes induced by vaccination with T-helper epitopes.
    Gjertsen MK; Saeterdal I; Saebøe-Larssen S; Gaudernack G
    J Mol Med (Berl); 2003 Jan; 81(1):43-50. PubMed ID: 12545248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential binding to frequent HLA-A alleles of p21 RAS derived peptides bearing oncogenic substitutions at position 12 or 13.
    Gouttefangeas C; Demeur C; Connan F; Balayn N; Choppin J; Tilkin-Mariamé AF
    Hum Immunol; 1997 Jul; 55(2):117-26. PubMed ID: 9361963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes.
    Horiguchi Y; Nukaya I; Okazawa K; Kawashima I; Fikes J; Sette A; Tachibana M; Takesako K; Murai M
    Clin Cancer Res; 2002 Dec; 8(12):3885-92. PubMed ID: 12473604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lysis of ras oncogene-transformed cells by specific cytotoxic T lymphocytes elicited by primary in vitro immunization with mutated ras peptide.
    Peace DJ; Smith JW; Chen W; You SG; Cosand WL; Blake J; Cheever MA
    J Exp Med; 1994 Feb; 179(2):473-9. PubMed ID: 8294861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme.
    Bondurant KL; Crew MD; Santin AD; O'Brien TJ; Cannon MJ
    Clin Cancer Res; 2005 May; 11(9):3446-54. PubMed ID: 15867247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a new HLA-A*0201-restricted CD8+ T cell epitope from hepatocellular carcinoma-associated antigen HCA587.
    Li B; Wang Y; Chen J; Wu H; Chen W
    Clin Exp Immunol; 2005 May; 140(2):310-9. PubMed ID: 15807856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 147.